RESUMO
INTRODUCTION: Chimeric antigen receptor T (CAR-T) cell therapy is an emerging treatment option for relapsed/refractory multiple myeloma (RRMM) that is a multi-step process involving various stakeholders. Appropriate education on the practical logistics is therefore paramount to ensure treatment success. METHODS: A group of key opinion leaders met to explore the key elements of setting up and running a CAR-T center in Brazil. For each step in the CAR-T cell therapy process, the experts agreed on basic requirements, gave their key recommendations from practical experience, and considered any remaining unanswered questions. RESULTS: This paper presents best-practice recommendations and advice on how to overcome common challenges for each step in the CAR-T cell therapy process, with a focus on the current situation in Brazil. Key themes throughout the process are collaboration within the multidisciplinary team and with the referring physician, along with communication and education for patients and their caregivers. CONCLUSION: We believe that the expert insights presented in this paper, in particular on optimal patient selection and timing of CAR-T cell therapy, will deepen understanding of the CAR-T process and aid implementation of this novel therapy for patients with RRMM in Brazil.
RESUMO
ABSTRACT Introduction Chimeric antigen receptor T (CAR-T) cell therapy is an emerging treatment option for relapsed/refractory multiple myeloma (RRMM) that is a multi-step process involving various stakeholders. Appropriate education on the practical logistics is therefore paramount to ensure treatment success. Methods A group of key opinion leaders met to explore the key elements of setting up and running a CAR-T center in Brazil. For each step in the CAR-T cell therapy process, the experts agreed on basic requirements, gave their key recommendations from practical experience, and considered any remaining unanswered questions. Results This paper presents best-practice recommendations and advice on how to overcome common challenges for each step in the CAR-T cell therapy process, with a focus on the current situation in Brazil. Key themes throughout the process are collaboration within the multidisciplinary team and with the referring physician, along with communication and education for patients and their caregivers. Conclusion We believe that the expert insights presented in this paper, in particular on optimal patient selection and timing of CAR-T cell therapy, will deepen understanding of the CAR-T process and aid implementation of this novel therapy for patients with RRMM in Brazil.
Assuntos
Imunoterapia Adotiva , Mieloma Múltiplo , Antígeno de Maturação de Linfócitos B , ImunoterapiaRESUMO
Errors in medication administration involve risks to patient safety. "Bar-Coding Medication Administration" is implemented to prevent these errors. Adoption by nurses is one of the main determinants of their effectiveness. The Hospital Italiano de Buenos Aires implemented BCMA 6 years ago, but its adoption rate still finds resistance in certain sectors. We conducted semi-structured interviews with nursing staff to explore the barriers to the use in low-usage wards and explore the current perceptions of nurses. While nurses recognised the safety and usefulness of the BCMA system, they reported many difficulties. The feedback obtained through this process was useful for the implementation team to plan future interventions, priorities and improvements on the system. The semi-structured interview methodology proved useful as a continuous monitoring strategy.
Assuntos
Erros de Medicação , Processamento Eletrônico de Dados , Humanos , Erros de Medicação/prevenção & controle , Sistemas de Medicação no Hospital , Segurança do Paciente , Preparações FarmacêuticasRESUMO
Since 2017, the Hospital Italiano de Buenos Aires, has a "Workstation on Wheels" project were nurses can access to a mobile application in order to register the drug's administration, vital signs and complete an early warning assessment scale of the hemodynamic state of the patient. Although the overall objective was to achieve at least 95% drug registration through this system, their use did not remain stable over time. Therefore, it was necessary to create an interdisciplinary team to make a diagnosis of the project situation and reasons for the low use rate. In this process, a re-implementation of the barcoding administration system was carried out, focusing on the nursing staff maintaining the use of the system over time. The aim of this paper is to describe the experience and lessons learned in the process of re-implementing the drug barcoding system at the patient's bedside.
Assuntos
Aplicativos Móveis , Processamento Eletrônico de Dados , Humanos , Recursos Humanos de Enfermagem , Sinais VitaisRESUMO
El complejo BAFF (factor activador de células B) compuesto por la citocina BAFF, APRIL y sus receptores -BAFF-R (BR3), TACI y BCMA- influyen en la sobrevida periférica, en la maduración de los linfocitos B y en el cambio de clase de las inmunoglobulinas, con múltiples implicaciones clínicas potenciales. Las funciones biológicas de BAFF y su relevancia en varios desórdenes clínicos -autoinmunes, neoplásicos, infecciosos, incluyendo las terapias BAFF dirigidas- son revisadas y discutidas en el presente artículo. Los niveles séricos de BAFF/APRIL se encuentran incrementados en las enfermedades autoinmunes en las que sus concentraciones se relacionan con los títulos de anticuerpos, actividad, progresión de la enfermedad e incluso compromiso orgánico, haciendo de su inhibición un blanco terapéutico atractivo
The BAFF complex (B cell activator factor) composed by the BAFF cytokine, APRIL and their receptors -BAFF-R (BR3), TACI, BCMA- influences B-lymphocyte maturation, peripheral survival and immunoglobulins class isotype switching, with multiple potential clinical implications. In this review we discuss BAFF biologic functions and it relevance in several clinical disorders -autoimmune, neoplastic, infectious and BAFF therapies-. BAFF/APRIL